A5023165826- Mental Health Treatment and Access
- Migration, Health and Trauma
- Schizophrenia research and treatment
- Diet and metabolism studies
- Child and Adolescent Psychosocial and Emotional Development
- Maternal Mental Health During Pregnancy and Postpartum
- Posttraumatic Stress Disorder Research
- Resilience and Mental Health
- Primary Care and Health Outcomes
- Poverty, Education, and Child Welfare
- Homelessness and Social Issues
- Child Abuse and Trauma
- Health and Conflict Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Psychiatric care and mental health services
- Mental Health and Psychiatry
- Global Maternal and Child Health
- Mental Health and Patient Involvement
- Racial and Ethnic Identity Research
- Health disparities and outcomes
- Cervical Cancer and HPV Research
- Pharmacology and Obesity Treatment
- Child and Adolescent Health
- Innovations in Medical Education
- Bipolar Disorder and Treatment
Boston University
2016-2024
National Institute of Mental Health
2024
National Institutes of Health
2024
Boston Medical Center
2016-2023
University School
2017-2022
Harvard University
2006-2021
Lemuel Shattuck Hospital
2011-2021
Columbia University
2017-2018
Virbac (France)
2018
Brandeis University
2017
<h3>Background</h3> While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated certain atypical antipsychotic agents, it remains unclear whether agents are directly affecting glucose metabolism or simply known risk factors for diabetes. <h3>Objective</h3> To study 2 drugs most clearly implicated (clozapine and olanzapine) risperidone using a frequently sampled intravenous tolerance test. <h3>Design</h3> A cross-sectional design stable,...
Article Abstract Objective: The goal of this 10-year naturalistic study was to examine, in clozapine-treated patients, the change cardiovascular risk factors following clozapine initiation and mortality estimates from disease. Method: Data were collected medical records January 1992 December 2003 included age, gender, race, diagnosis, family history diabetes, age at for patients with schizophrenia or schizoaffective disorder (DSM-IV criteria). Clozapine dosage laboratory results recorded...
The increasing prevalence of overweight and obesity has become a priority public health issue in the United States. Forty to 62% people with schizophrenia are obese or (1, 2). High morbidity mortality may be attributed an unhealthy lifestyle such as poor diet, lack exercise, smoking, substance abuse (3). Obesity is associated greater risk developing hypertension, type 2 diabetes, coronary heart disease, stroke, death, reduced quality life compared that found general population (4, 5). We...
Weight gain is commonly observed with olanzapine treatment and can increase the risk for obesity, cardiovascular disease, hypertension, diabetes mellitus. This study examined effectiveness of sibutramine, an approved weight loss agent, in overweight obese subjects taking schizophrenia or schizoaffective disorder.Each subject had a DSM-IV diagnosis disorder, been stable dose at least 4 months, body mass index >/=30 kg/m(2) >/=27 plus one factor. In 12-week double-blind, randomized,...
Olanzapine treatment has been associated with clinically meaningful weight increases, hypertriglyceridemia, insulin resistance, and diabetes mellitus. There are few options for olanzapine responders who fail other antipsychotic agents. Aripiprazole is a potent (high-affinity) partial agonist at D2 5-HT1A receptors antagonist 5-HT2A receptor less gain than olanzapine. We report the results of 10-week placebo-controlled, double-blind crossover study that examined 15 mg/d aripiprazole's effects...
Objective: We conducted this 6‐week open‐label trial to examine the effects of adjunctive aripiprazole in clozapine‐treated subjects on weight, lipid and glucose metabolism, as well positive negative symptoms schizophrenia. Method: Ten received augmentation; eight completed two ended at week 4. Eighty percent were male, mean age was 38.7 ± 8.9 years clozapine dose 455 83 mg daily. Results: There a significant decrease weight ( P = 0.003), body mass index 0.004), fasting total serum...
We conducted a retrospective epidemiologic study assessing the incidence of new-onset diabetes mellitus presenting as diabetic ketoacidosis in patients with schizophrenic disorders (ICD-9 295.0-295.9; referred to "schizophrenia patients" hereafter) treated atypical antipsychotic agents.The identification and review records were achieved by using an electronic database linking administrative clinical laboratory data between January 1, 1995, December 31, 2001. The main outcome measure was or...
The effect that attending a 1-day workshop on Good Psychiatric Management (GPM) had attitudes about borderline personality disorder (BPD) was assessed among 297 clinicians. Change recorded by comparing before and after scores 9-item survey previously developed to assess the effects of workshops Systems Training for Emotional Predictability Problem Solving (STEPPS). Participants reported decreased inclination avoid patients, dislike belief BPD's prognosis is hopeless, as well increased...
Mental health disparities based on minority racial status are well characterized, including inequities in access, symptom severity, diagnosis, and treatment. For African Americans, racism may affect mental through factors such as poverty segregation, which have operated since slavery. While the need to address medical training has been recognized, there few examples of formal didactic curricula psychiatric literature. Antiracism didactics during psychiatry residency provide a unique...
Fan X, Borba CPC, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC. Metabolic effects of adjunctive aripiprazole in clozapine‐treated patients with schizophrenia. Objective: This study examined the therapy on metabolism Method: In an 8‐week randomized, double‐blind, placebo‐controlled study, subjects received either (15 mg/day) or placebo. At baseline and week 8, metabolic parameters were assessed by frequently sampled intravenous glucose tolerance test, nuclear magnetic resonance...
Between 1989 and 2004, Liberia experienced a devastating civil war that resulted in widespread trauma with almost no mental health infrastructure to help citizens cope. In 2009, the Liberian Ministry of Health Social Welfare collaborated researchers from Massachusetts General Hospital conduct rapid needs assessment survey local key informants (n = 171) examine impact post-war events on emotional behavioral problems of, functional limitations appropriate treatment settings for youth aged...
There is a dearth of qualitative studies exploring the lived experiences frontline healthcare personnel (HCP) during coronavirus disease (COVID-19) pandemic. We examined workplace stressors, psychological manifestations said and coping strategies reported through coded open-text responses from 1024 online surveys completed over two months by 923 HCP participating in three nationwide cohorts Spring 2020. Our findings suggest that risk, job insecurity, frustration with hospital administration,...
Objective: This study sought to examine the effectiveness of sibutramine, a weight loss agent, on clozapine‐associated gain. Method: was 12‐week double‐blind, placebo controlled, randomized trial sibutramine for in obese clozapine‐treated schizophrenia or schizoaffective disorder subjects. Results: Ten patients were enrolled into group and 11 group. There no significant baseline differences between two groups age, gender, education, ethnicity, diagnosis, weight, body mass index (BMI), blood...
Article Abstract Objective: Clozapine and olanzapine treatment has been associated with insulin resistance in nonobese schizophrenia patients. Much less is known regarding other agents such as quetiapine. The objective of this study was to compare matched olanzapine- quetiapine-treated patients normal controls on measures glucose metabolism. Method: A cross-sectional comparison olanzapine-treated (body mass index < 30.0 kg/m2) subjects (DSM-IV) using a frequently sampled intravenous...